Free tool
FAERS Monitor: Invokamet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204353 or its brand name (Invokamet, Canagliflozin, Metformin Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
1,695
Serious
965
57% of reports
Hospitalization
609
Death reported
21
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- osteomyelitis197
- toe amputation192
- diabetic ketoacidosis161
- acute kidney injury101
- cellulitis92
- diabetic foot infection84
- blood glucose increased80
- gangrene80
- nausea74
- off label use73
- diarrhoea71
- weight decreased66
- diabetic foot63
- leg amputation62
- foot amputation59
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2014 | 6 |
| 2015 | 292 |
| 2016 | 350 |
| 2017 | 255 |
| 2018 | 350 |
| 2019 | 185 |
| 2020 | 93 |
| 2021 | 47 |
| 2022 | 32 |
| 2023 | 34 |
| 2024 | 27 |
| 2025 | 13 |
| 2026 | 11 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,464 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| diabetic foot infectionSignal | 84 | 782.7 | 631.1 | 60,960 |
| foot amputationSignal | 59 | 524.6 | 406.0 | 29,083 |
| toe amputationSignal | 192 | 487.6 | 425.5 | 89,262 |
| diabetic footSignal | 63 | 260.7 | 204.1 | 15,715 |
| leg amputationSignal | 62 | 189.5 | 148.2 | 11,270 |
| gangreneSignal | 80 | 166.9 | 134.6 | 12,861 |
| osteomyelitisSignal | 197 | 136.5 | 119.6 | 26,105 |
| diabetic ketoacidosisSignal | 161 | 83.7 | 72.2 | 13,005 |
| cellulitisSignal | 92 | 22.7 | 18.6 | 1,887 |
| acute kidney injurySignal | 101 | 8.2 | 6.8 | 635 |
| blood glucose increasedSignal | 80 | 5.3 | 4.3 | 275 |
| weight decreasedSignal | 66 | 2.9 | 2.3 | 83 |
| diarrhoea | 71 | 1.4 | 1.1 | 7 |
| nausea | 74 | 1.2 | 0.9 | 2 |
| off label use | 73 | 1.0 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.